In many cancers, mutation to these and other functionally related genes have long been used to predict sensitivity to selective poly (ADP-ribose) polymerase (PARP) inhibitors such as Niraparib, Olaparib, Talazoparib, Rucaparib, and Veliparib [7]. Here, PARP1 is linked to cancer.